BioCentury
ARTICLE | Company News

Teva, Allergan settle working capital dispute

February 16, 2018 8:49 PM UTC

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) said Allergan plc (NYSE:AGN) agreed to pay Teva $700 million to settle a dispute that arose after Teva purchased Allergan's global generic pharmaceuticals business.

In November 2017, Teva said in an SEC filing that the final cash consideration for the deal needed adjustments. Teva suggested that Allergan pay $1.4 billion and noted that the final contractual adjustment would be determined in arbitration...